These findings support the use of DHA as a candidate therapeutic agent for minimizing HER2-mediated oncogenesis in breast cancer cells by disturbing a PPARγ-independent lipogenic phenotype associated with HER2 overexpression. The gene discussed is PPARG; the disease is breast carcinoma.